- Download App
Cancer caregivers
Biomarker testing
Biomarker testing is a powerful tool in cancer treatment that examines specific molecules, genes, or proteins in a person’s tissue, blood, or other bodily fluids to provide insight into their cancer. Biomarkers can offer important information about a cancer’s type, behavior, and the best treatment approach, enabling a personalized or precision medicine approach to cancer care.
Here’s a comprehensive look at how biomarker testing works, its role in cancer treatment, and how it helps improve outcomes for cancer patients.
Biomarker testing
What Are Biomarkers?
Biomarkers are measurable indicators of biological processes or conditions. In cancer, biomarkers often refer to specific genetic mutations, proteins, or other molecular changes in cancer cells that can influence the disease’s development, growth, and response to treatment. Biomarkers can fall into several categories:
- Diagnostic Biomarkers: Used to detect cancer and help diagnose its type.
- Prognostic Biomarkers: Predict the likely course of the disease and help estimate survival rates or disease progression.
- Predictive Biomarkers: Indicate how likely a cancer is to respond to a specific treatment, guiding the choice of therapy.
- Pharmacodynamic Biomarkers: Show how a patient’s cancer is responding to treatment.
- Risk Biomarkers: Assess an individual’s likelihood of developing cancer.
Types of Biomarkers Used in Cancer Treatment
Genetic (or Genomic) Biomarkers:
- These are specific gene mutations or changes in DNA within cancer cells.
- They include alterations in genes like EGFR, KRAS, and BRAF, which are often used to guide targeted therapies.
- Example: An EGFR mutation in lung cancer suggests that drugs targeting EGFR, like erlotinib, may be effective.
- Pharmacodynamic Biomarkers: Show how a patient’s cancer is responding to treatment.
- Risk Biomarkers: Assess an individual’s likelihood of developing cancer.
Protein Biomarkers:
- Some cancers overproduce certain proteins, which can help identify the type of cancer or predict treatment response.
- Example: HER2 is a protein found in excess in some breast cancers, guiding the use of HER2-targeted therapies like trastuzumab.
Immune Biomarkers:
- Biomarkers like PD-L1, a protein that can help tumors evade the immune system, are used to predict whether immunotherapy might be effective
- Example: PD-L1 expression in cancers like melanoma or lung cancer suggests a patient may benefit from immune checkpoint inhibitors, such as pembrolizumab.
Hormone Receptors:
- Biomarkers like estrogen and progesterone receptors (ER and PR) in breast cancer indicate the cancer is hormone-driven and may respond to hormone therapy.
- Example: ER-positive breast cancer often responds well to hormone-blocking treatments like tamoxifen or aromatase inhibitors.
How Biomarker Testing Works
Biomarker testing is typically performed on a tissue sample from a biopsy or on a blood sample. Here’s how the testing process generally works:
Sample Collection:
- A biopsy of the tumor or a blood sample is collected for analysis. This sample contains the cancer cells or their products (like DNA, RNA, or proteins) that carry biomarkers.
Laboratory Analysis:
- Advanced technologies, such as next-generation sequencing (NGS) or immunohistochemistry (IHC), are used to analyze the sample.
- For genetic biomarkers, NGS can provide a detailed picture of the tumor’s mutations. For protein biomarkers, IHC can show the presence and quantity of specific proteins in the cells.
Interpretation of Results:
- The test results are interpreted to identify relevant biomarkers that can guide treatment decisions. For example, a patient with HER2-positive breast cancer would likely benefit from HER2-targeted therapy.
Use in Treatment Planning:
- Based on the biomarkers found, doctors can customize treatment options for each patient, focusing on therapies likely to be effective for their specific cancer.
The Role of Biomarker Testing in Cancer Treatment
Biomarker testing plays a critical role in each phase of cancer care, helping personalize treatment and improve outcomes:
Selecting Targeted Therapy:
- Targeted therapies are drugs designed to attack specific mutations or proteins within cancer cells, sparing healthy cells and reducing side effects.
- Biomarker testing identifies mutations in genes like EGFR, ALK, BRAF, or HER2, helping doctors choose therapies targeting these mutations.
- Example: In non-small cell lung cancer (NSCLC), EGFR mutations guide the use of EGFR inhibitors, like gefitinib or erlotinib.
Guiding Immunotherapy:
- Immunotherapy drugs work by activating the immune system to attack cancer cells. However, they’re effective in only some patients.
- Biomarkers like PD-L1 expression or mismatch repair (MMR) deficiency can predict whether immunotherapy will be effective.
- Example: PD-L1 expression in advanced lung cancer can guide the use of immune checkpoint inhibitors, such as pembrolizumab.
Optimizing Hormone Therapy:
- For hormone-driven cancers, such as certain breast or prostate cancers, biomarker tests determine if cancer relies on hormones for growth.
- If biomarkers like ER or PR are present, hormone-blocking treatments can slow down cancer growth.
- Example: An ER-positive breast cancer patient may benefit from tamoxifen, which blocks estrogen from fueling cancer growth.
Monitoring Treatment Response and Adjusting Therapy:
- Biomarkers can help monitor how well a cancer is responding to treatment. Changes in biomarker levels can indicate whether treatment is effective or if the cancer is progressing.
- Example: In chronic myeloid leukemia (CML), levels of the BCR-ABL fusion gene are monitored. If levels drop, it suggests the therapy is working; if not, a different approach may be needed.
Assessing Prognosis:
- Some biomarkers give information about how aggressive the cancer is, its likelihood of recurrence, and overall survival rates.
- Example: In breast cancer, high levels of Ki-67 (a marker of cell proliferation) may indicate a more aggressive form, potentially leading to more intensive treatment.
Examples of Biomarkers in Common Cancers
Breast Cancer:
- HER2: Guides HER2-targeted therapies (e.g., trastuzumab).
- ER/PR: Indicates hormone-driven cancer; guides hormone therapy.
- BRCA1/BRCA2: Identifies patients who may benefit from PARP inhibitors.
Lung Cancer:
- EGFR: Predicts response to EGFR inhibitors (e.g., erlotinib).
- ALK: Guides the use of ALK inhibitors (e.g., crizotinib).
- PD-L1: Suggests potential benefit from immunotherapy.
Colorectal Cancer:
- KRAS: Helps determine response to anti-EGFR drugs (patients with KRAS mutations generally do not respond).
- MMR/MSI: Identifies candidates for immunotherapy in cases with mismatch repair deficiency.
Melanoma:
- BRAF: Directs the use of BRAF inhibitors (e.g., vemurafenib).
- PD-L1: Suggests immunotherapy as a treatment option.
Prostate Cancer:
- AR (Androgen Receptor): Guides the use of androgen-deprivation therapy.
- BRCA1/BRCA2: In advanced cases, may indicate benefit from PARP inhibitors.
Benefits of Biomarker Testing in Cancer Treatment
Personalized Therapy:
- Biomarker testing enables doctors to tailor treatments to the unique characteristics of a patient’s cancer, improving the chances of success.
Higher Effectiveness:
- By selecting treatments that target specific cancer mutations, biomarker testing often results in better outcomes and fewer side effects.
Reduced Trial-and-Error:
- Testing helps avoid ineffective treatments, saving time and reducing the impact of unnecessary side effects.
Monitoring and Adjusting Treatments:
- Biomarkers allow doctors to monitor cancer progression and response, adjusting therapies as needed.
Enhanced Prognosis and Quality of Life:
- With more accurate treatment options, patients have a better chance of improved survival and quality of life.
Limitations of Biomarker Testing
- Not All Cancers Have Targetable Biomarkers: Many cancers lack specific biomarkers, limiting the benefits of biomarker-guided treatment.
- Availability and Cost: Biomarker testing can be expensive and is not always covered by insurance.
- Interpretation Challenges: Not all biomarkers clearly predict treatment response, making interpretation complex.
- Resistance to Targeted Therapies: Cancers can develop resistance to targeted therapies over time, requiring alternative treatments.
Enhanced Prognosis and Quality of Life:
Research continues to identify new biomarkers, expanding the potential of precision medicine. Advances like liquid biopsies (which detect tumor DNA in blood samples) are making biomarker testing less invasive, enabling frequent monitoring of treatment response and early detection of recurrence.
In the future, biomarker testing is expected to play an even larger role in making cancer treatment highly personalized, increasing the effectiveness of therapies, reducing side effects, and improving